• 

  Alzheimer’s Drug Trials Have Had a 99% Failure Rate. The Good News: There Are Currently More Than 100 in the Pipeline
• 

  Phil’s Journal: Being Part of Scientific History, or, a New Phase of the Biogen Trial
• 

  This Discovery May Speed Up Alzheimer’s Drug Testing
• 

  Phil’s Journal: Trials and Tribulations, or, My Latest Experience in Biogen Research
• 

  Cancer Drug Nilotinib Shows Promise for Treatment of Alzheimer’s
• 

  A New Drug for Agitation in Alzheimer’s Progresses Through Trials
• 

  Phil’s Journal: Waiting While Approval for Biogen’s Alzheimer’s Drug is Delayed, Yet Again
• 

  Phil’s Journal: Pandemic Disrupts Alzheimer’s Clinical Trials. Including Mine
• 

  Phil’s Journal: My Good Friend Is the First to Receive Biogen’s Alzheimer’s Drug in New Trial
• 

  Phil’s Journal: When Alzheimer’s Trials Are Cancelled, Notifying Study Participants in the Most ‘Humane’ Way
• 

  New Alzheimer’s Trial Aims to Defeat Amyloid Before Symptoms Develop
• 

  Another Alzheimer’s Trial Cancelled: Lilly, Roche Drugs Fail to Reduce Beta-Amyloid
• 

  Alzheimer’s Drug Targeting Tau Protein to Start New Clinical Trials
• 

  New ‘Basket’ Trials Target Dementia Through Precision Medicine
• 

  China Approves ‘Seaweed Drug’ for Treatment of Alzheimer’s

Previous8910Next